Welcome to our dedicated page for Grifols S A SEC filings (Ticker: GRFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Grifols, S.A. (GRFS) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures, primarily on Form 20‑F and Form 6‑K. As a foreign private issuer and global healthcare company focused on plasma-derived medicines and transfusion medicine, Grifols uses these filings to report financial performance, governance decisions and other material information to investors.
In its recent 6‑K reports, Grifols has provided half‑year and quarterly results that detail revenue trends, adjusted EBITDA, free cash flow and leverage metrics. These filings show how the Biopharma segment, led by immunoglobulin, albumin, Alpha‑1 and specialty proteins, contributes to growth, and how the Diagnostic business performs in areas such as blood typing solutions and molecular donor screening. They also describe the company’s Value Creation Plan, deleveraging efforts and liquidity position.
Other 6‑K submissions cover board and governance matters, including amendments to the internal regulations of the Board of Directors, the renaming and expanded remit of the Sustainability, Communication and Reputation Committee, and changes in the secretary and vice‑secretary roles of the Board. Dividend declarations, such as the approval of an interim cash dividend, are also disclosed through these reports.
On Stock Titan, each Grifols filing is accompanied by AI-powered summaries that explain the key points in accessible language, helping users understand complex financial tables and legal language. Investors can quickly locate annual reports (20‑F), current reports (6‑K) with earnings presentations and press releases, and other relevant documents. Real-time updates from EDGAR ensure that new filings appear promptly, while structured views of the information help users track topics such as revenue mix, leverage ratio, capital allocation and governance changes for GRFS over time.
Grifols, S.A. reports that its Board of Directors has decided to start a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary that is the parent of its U.S. Biopharma business. The company stresses that any IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and there is no assurance that it will be undertaken or completed. Grifols also notes that, regardless of whether any IPO occurs, its shares will continue trading in Spain on the mercado continuo, and this communication does not constitute an offer or solicitation to buy or sell securities.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.
Grifols, S.A. reports a change in its Board support roles. The Board of Directors unanimously approved, with effect from 1 January 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés. At the same time, Mrs. Núria Martín Barnés has been appointed as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán. The decision followed a favourable report from the Appointments and Remuneration Committee.
Brandes Investment Partners, L.P. filed an amended Schedule 13G reporting beneficial ownership in Grifols SA. As of 09/30/2025, Brandes reports beneficial ownership of 29,126,291.55 ADRs, representing 19.6% of the class.
The filer reports no sole or shared voting power and shared dispositive power over 29,126,291.55 ADRs. Item 4 also notes holdings of 22,107,370 ordinary shares and 29,126,291.55 ADRs for which dispositive power is shared. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Grifols (GRFS) reported Q3 2025 results with revenue of EUR 1,865 million and quarterly group profit of EUR 127 million, reflecting strong momentum in its Value Creation Plan. Year-to-date revenues reached EUR 5,542 million, up 7.7% at constant currency, while adjusted EBITDA was EUR 1,358 million with a 24.5% margin. Q3 adjusted EBITDA was EUR 482 million, up 8.8% at constant currency, with a 25.8% margin.
Year-to-date net profit was EUR 304 million, up 245%. Free cash flow pre-M&A and pre-dividend was EUR 203 million in Q3, bringing the nine-month total to EUR 188 million, a EUR 257 million improvement versus last year. Leverage improved to 4.2x from 5.1x a year ago, and liquidity rose to EUR 1,475 million.
Growth was led by Biopharma, with a 9.1% constant-currency increase year-to-date and 10.9% in Q3. Immunoglobulin revenues rose 14.4% year-to-date, while subcutaneous IG grew more than 60%. Albumin declined 3.9% year-to-date due to pricing adjustments in China. The Diagnostic business generated EUR 479 million year-to-date, up 1.4%, with FDA approval to begin manufacturing Gel Cards and reagent Red Blood Cells in San Diego. Grifols noted potential full-year FX headwinds of approximately EUR 70 million to adjusted EBITDA if current rates persist.
Grifols’ H1-25 results show solid operating momentum and meaningful deleveraging. Revenue rose 7.0% cc to EUR 3.68 bn, fueled by Biopharma +8.2% cc with IG volumes up 12.5% and SCIG +66%. Adjusted EBITDA climbed 12.7% cc to EUR 876 m, lifting margin 80 bps to 23.8% despite IRA headwinds. Net profit jumped nearly 4-fold to EUR 177 m, aided by lower restructuring costs and improved finance charges.
Free cash flow pre-M&A improved EUR 182 m YoY to -14 m (EUR 30 m positive in Q2); leverage fell to 4.2× (5.5× a year earlier) with liquidity of EUR 1.4 bn. The company reinstated a EUR 0.15/share dividend, finalized Biotest delisting to reach 80.3% ownership (EUR 108 m outlay), and reiterated FY-25 guidance while raising FCF pre-M&A outlook to EUR 375-425 m. Pipeline execution remains on track, targeting EU launch of fibrinogen in Q4-25 and US launch H1-26.
Management warns that a weaker USD will pressure reported H2 revenue & EBITDA, but expects neutral impact on profit, leverage and FCF through cost levers. Segment detail: Diagnostic +2.8% cc, BioSupplies -31.8% cc. Albumin declined 3.7% cc YTD but returned to growth in Q2. Overall, the Value Creation Plan is delivering margin gains, cash-flow recovery and balance-sheet repair, though free cash flow and net debt (EUR 9.1 bn) remain key watch points.
Grifols (GRFS) has declared an interim cash dividend of €0.15 per share against FY-2025 earnings. The Board approved the payment on 28 Jul 2025, representing a total cash outlay of €102.1 m after excluding 7.0 m treasury shares. Key timetable:
- Last trading date: 8 Aug 2025
- Ex-dividend: 11 Aug 2025
- Record date: 12 Aug 2025
- Payment date: 13 Aug 2025